Advertisement

Drugs

, Volume 77, Issue 10, pp 1123–1129 | Cite as

Valbenazine: First Global Approval

  • Esther S. KimEmail author
AdisInsight Report

Abstract

Valbenazine (Ingrezza™) is an orally bioavailable, selective, vesicular monoamine transporter 2 (VMAT2) inhibitor being developed by Neurocrine Biosciences for the treatment of various central nervous system disorders. Valbenazine has been approved in the USA for the treatment of adults with tardive dyskinesia (TD), is at various stages of development in other countries for TD and is in phase 2 development in the USA for Tourette syndrome. This article summarizes the milestones in the development of valbenazine leading to its first global approval in the USA for the treatment of adults with TD.

Notes

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. E. S. Kim is a salaried employee of Adis, Springer SBM.

Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/7C48F06022B8809D.

References

  1. 1.
    Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (NY). 2013. doi: 10.7916/D88P5Z71.Google Scholar
  2. 2.
    Aia PG, Revuelta GJ, Cloud LJ, et al. Tardive dyskinesia. Curr Treat Options Neurol. 2011;13(3):231–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Grigoriadis DE, Smith E, Hoare SRJ, et al. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharm Exp Ther. 2017. doi: 10.1124/jpet.116.239160.Google Scholar
  4. 4.
    US FDA. FDA approves first drug to treat tardive dyskinesia [media release]. 11 Apr 2017. https://www.fda.gov.
  5. 5.
    Neurocrine Biosciences Inc. IngrezzaTM (valbenazine) capsules: US prescribing information. 2017. https://www.fda.gov. Accessed 3 May 2017.
  6. 6.
    Adis Insight. Drug profile: valbenazine. 2017. http://www.adisinsight.springer.com. Accessed 3 May 2017.
  7. 7.
    Mitsubishi Tanabe Pharma Corporation. Business briefing—open up the future. 2016. http://www.mt-pharma.co.jp. Accessed 5 May 2017.
  8. 8.
    Neurocrine Biosciences. Neurocrine Biosciences and Mitsubishi Tanabe Pharma announce agreement to develop and commercialize VMAT2 inhibitor NBI-98854 for movement disorders in Japan and other select Asian markets [media release]. 31 Mar 2015. http://www.neurocrine.com/.
  9. 9.
    Neurocrine Biosciences. Neurocrine Biosciences announces notice of allowance for composition of matter patent on VMAT2 inhibitor [media release]. 23 Jun 2011. http://www.neurocrine.com.
  10. 10.
    Neurocrine Biosciences. Neurocrine Biosciences announces additional European and United States patents issued on proprietary VMAT2 inhibitor [media release]. 23 Jan 2013. http://www.neurocrine.com/.
  11. 11.
    Hauser RA, Factor SA, Marder SR, et al. KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174(5):476–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Factor S, Comella C, Correll C, et al. Efficacy of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of a long-term study (KINECT 3 extension) [abstract no. S56.005]. Neurology. 2017;88(16 Suppl).Google Scholar
  13. 13.
    National Library of Medicine. Clinicaltrials.gov. 2017. https://clinicaltrials.gov/. Accessed 12 May 2017.
  14. 14.
    Neurocrine Biosciences. Neurocrine Biosciences reports first quarter 2017 results [media release]. 9 May 2017. http://www.neurocrine.com/.
  15. 15.
    O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Neurocrine Biosciences. Neurocrine announces phase IIb results of VMAT2 inhibitor NBI-98854 for treatment of tardive dyskinesia [media release]. 9 Sep 2013. http://www.neurocrine.com/.
  17. 17.
    Bari M, Shiwach R, Jimenez R, et al. Open-label extension of kinect: a phase 2 study of valbenazine (NBI-98854) for tardive dyskinesia [abstract no. S27.001]. Neurology. 2016;86(16 Suppl 1).Google Scholar
  18. 18.
    Neurocrine Biosciences. Neurocrine announces phase II results of VMAT2 inhibitor NBI-98854 for treatment of tardive dyskinesia [media release]. 26 Mar 2012. http://www.neurocrine.com/.
  19. 19.
    Neurocrine Biosciences. Neurocrine Biosciences announces successful phase IIa clinical trial for VMAT2 inhibitor [media release]. 5 Apr 2011. http://www.neurocrine.com/.
  20. 20.
    Neurocrine Biosciences. Neurocrine announces completion of phase II clinical study of VMAT2 inhibitor INGREZZA™ (valbenazine) in adults with Tourette Syndrome [media release]. 17 Jan 2017. http://www.neurocrine.com/.
  21. 21.
    Remington G, Comella C, Grigoriadis D, et al. Safety and tolerability of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of long-term exposure data from three studies [abstract no. M150]. Neuropsychopharmacology. 2016;41(Suppl S1):S212–3.Google Scholar
  22. 22.
    Neurocrine Biosciences. Neurocrine announces initiation of phase II clinical study of VMAT2 inhibitor valbenazine in children and adolescents with Tourette Syndrome [media release]. 2 Feb 2016. http://www.neurocrine.com/.
  23. 23.
    Neurocrine Biosciences. Neurocrine announces initiation of a long-term phase II clinical study of VMAT2 inhibitor valbenazine in Tourette syndrome [media release]. 28 Jul 2016. http://www.neurocrine.com/.

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.SpringerMairangi Bay 0754New Zealand

Personalised recommendations